BIOTEM chosen by the European Commission to be part of the e‑FabRIC consortium to develop an innovative broad-spectrum therapeutic against emerging viruses with pandemic potential
HORIZON-HLTH-2023-DISEASE-03 / e-FabRIC – Number: 101137157
Apprieu, France, January 31, 2024 – 10:00 CET – BIOTEM, a hybrid Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) which provides high added value solutions for the production and characterization of recombinant antibodies, announces its participation in the e‑FabRIC1 consortium. This initiative unites top universities and European companies to bolster global health and preparedness.
The aim of this European project coordinated by Fabentech is to develop an innovative broad-spectrum antiviral therapy to combat new emerging infectious diseases with pandemic potential, particularly those caused by viruses in the Sarbecovirus family.
Considered to be one of the riskiest viruses, Sarbecoviruses are responsible for severe respiratory pathologies in humans, coupled with a high mortality rate and strong mutagenic capacities.
>> Learn more and read the press release: here
 enhanced manufacturing of broadly potent equine polyclonal Fab with a Rational Immunization strategy against Coronavirus